![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 50, 41636-41644, December 16, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




1
From the
Department of Internal Medicine, Division of Hematology-Oncology and Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan 48109 and the
Medical Scientist Training Program, University of Michigan, Ann Arbor, Michigan 48109
The stem cell leukemia (SCL) transcription factor is essential for vertebrate hematopoiesis. Using the powerful zebrafish model for embryonic analysis, we compared the effects of either reducing or ablating Scl using morpholino-modified antisense RNAs. Ablation of Scl resulted in the loss of primitive and definitive hematopoiesis, consistent with its essential role in these processes. Interestingly, in embryos with severely reduced Scl levels, erythroid progenitors expressing gata1 and embryonic globin developed. Erythroid maturation was deficient in these Scl hypomorphs, supporting that Scl was required both for the erythroid specification and for the maturation steps, with maturation requiring higher Scl levels than specification. Although all hematopoietic functions were rescued by wild-type Scl mRNA, an Scl DNA binding mutant rescued primitive and definitive hematopoiesis but did not rescue primitive erythroid maturation. Together, we showed that there is a distinct Scl hypomorphic phenotype and demonstrated that distinct functions are required for the roles of Scl in the specification and differentiation of primitive and definitive hematopoietic lineages. Our results revealed that Scl participates in multiple processes requiring different levels and functions. Further, we identified an Scl hypomorphic phenotype distinct from the null state.
Received for publication, July 22, 2005 , and in revised form, October 6, 2005.
* This work was supported by National Institutes of Health Grant K22-CA095024-02 (to S. E. L.) and a grant from the University of Michigan Medical Scientist Training Program (to M. J. K). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Dept. of Internal Medicine, Division of Hematology-Oncology and Cellular and Molecular Biology Program, University of Michigan, Medical Sciences Bldg. I, Rm. 5315, 1150 W. Medical Center Dr., Ann Arbor, MI 48109-0612. Tel.: 734-615-6412; Fax: 734-615-7012; E-mail: suslyons{at}umich.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. T. Kassouf, H. Chagraoui, P. Vyas, and C. Porcher Differential use of SCL/TAL-1 DNA-binding domain in developmental hematopoiesis Blood, August 15, 2008; 112(4): 1056 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Villablanca, A. Pistocchi, F. A. Court, F. Cotelli, C. Bordignon, M. L. Allende, C. Traversari, and V. Russo Abrogation of Prostaglandin E2/EP4 Signaling Impairs the Development of rag1+ Lymphoid Precursors in the Thymus of Zebrafish Embryos J. Immunol., July 1, 2007; 179(1): 357 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Patterson, M. Gering, C. E. Eckfeldt, A. R. Green, C. M. Verfaillie, S. C. Ekker, and R. Patient The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish Blood, March 15, 2007; 109(6): 2389 - 2398. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. de la Grange, F. Armstrong, V. Duval, M.-C. Rouyez, N. Goardon, P.-H. Romeo, and F. Pflumio Low SCL/TAL1 expression reveals its major role in adult hematopoietic myeloid progenitors and stem cells Blood, November 1, 2006; 108(9): 2998 - 3004. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |